NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia — Oct 8th, 2024

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla., October 08, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express...

NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation — Sep 23rd, 2024

Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET FT. MYERS, Fla., September 23, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cle...

NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia — Oct 8th, 2024

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla., October 08, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express...

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 — Oct 15th, 2024

FORT MYERS, Fla., October 15, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company ...

NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia — Oct 8th, 2024

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla., October 08, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express...

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 — Oct 15th, 2024

FORT MYERS, Fla., October 15, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company ...

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 — Oct 15th, 2024

FORT MYERS, Fla., October 15, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company ...

NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia — Oct 8th, 2024

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla., October 08, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express...

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 — Oct 15th, 2024

FORT MYERS, Fla., October 15, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company ...

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Oct 8th, 2024

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the...

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Oct 8th, 2024

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the...

NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia — Oct 8th, 2024

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla., October 08, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express...

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 — Oct 15th, 2024

FORT MYERS, Fla., October 15, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company ...

NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia — Oct 8th, 2024

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla., October 08, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express...

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 — Oct 15th, 2024

FORT MYERS, Fla., October 15, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company ...

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Oct 8th, 2024

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the...

NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia — Oct 8th, 2024

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla., October 08, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express...

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Oct 8th, 2024

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the...

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 — Oct 15th, 2024

FORT MYERS, Fla., October 15, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company ...

NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia — Oct 8th, 2024

New test fills unmet need for faster AML biomarker testing, expanding NeoGenomics’ broad oncology testing portfolio FT. MYERS, Fla., October 08, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express...

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Oct 8th, 2024

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the...

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Oct 8th, 2024

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the...

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Oct 8th, 2024

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the...

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 — Oct 15th, 2024

FORT MYERS, Fla., October 15, 2024--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company ...

NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Oct 8th, 2024

A downtrend has been apparent in NeoGenomics (NEO) lately. While the stock has lost 6.6% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the...